Palexia (Tapentadol)

Tapentadol is an opioid analgesic that acts within the central nervous system to relieve pain.

• Acute postoperative pain: provides effective relief when non‑opioid analgesics are insufficient.
• Chronic musculoskeletal pain: helps reduce pain intensity in conditions such as osteoarthritis.
• Neuropathic pain associated with diabetic peripheral neuropathy: alleviates burning and shooting pain sensations.
• Cancer‑related pain: contributes to multimodal pain control in oncology patients.
• Severe trauma pain: offers strong analgesia during the acute phase of injury.

• Tapentadol exerts its analgesic effect through a dual mechanism: it is a μ‑opioid receptor agonist that activates opioid pathways, and it inhibits the reuptake of norepinephrine, enhancing descending inhibitory pain pathways in the central nervous system. This combined action reduces the perception of pain without relying solely on opioid receptor activation.

Tapentadol may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

• Nausea
• Constipation
• Dizziness
• Somnolence
• Headache
• Dry mouth

Serious or Rare Side Effects

• Respiratory depression
• Seizures
• Severe hypotension
• Serotonin syndrome
• Allergic reactions such as rash or angio‑edema
• Dependence or abuse potential

When prescribing Tapentadol, clinicians should consider several safety aspects.

• Assess pain severity and prior opioid use: ensure appropriate indication before initiating therapy.
• Monitor for respiratory depression: especially during dose titration or in patients with pulmonary disease.
• Evaluate renal and hepatic function: dose adjustments may be required in impairment.
• Avoid concomitant CNS depressants: increased risk of sedation and respiratory effects.
• Counsel patients on signs of dependence: educate about proper use and storage.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Tapentadol can interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

• MAO inhibitors: risk of hypertensive crisis or serotonin syndrome.
• CNS depressants (benzodiazepines, barbiturates): heightened respiratory depression.
• Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase tapentadol plasma levels.

Moderate Interactions (Monitor Closely)

• Serotonergic agents (SSRIs, SNRIs, tramadol): potential for serotonin syndrome.
• Antihypertensives: additive hypotensive effect.
• Diuretics: may exacerbate orthostatic hypotension.